Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver Metastases
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Purpose: To evaluate the efficacy and tolerability of high-dose stereotactic body radiation therapy (SBRT) for the treatment of patients with one to three hepatic metastases. Patients and Methods: Patients with one to three hepatic lesions and maximum individual tumor diameters less than 6 cm were enrolled and treated on a multi-institutional, phase I/II clinical trial in which they received SBRT delivered in three fractions. During phase I, the total dose was safely escalated from 36 Gy to 60 Gy. The phase II dose was 60 Gy. The primary end point was local control. Lesions with at least 6 months of radiographic follow-up were considered assessable for local control. Secondary end points were toxicity and survival. Results: Forty-seven patients with 63 lesions were treated with SBRT. Among them, 69% had received at least one prior systemic therapy regimen for metastatic disease (range, 0 to 5 regimens), and 45% had extrahepatic disease at study entry. Only one patient experienced grade 3 or higher toxicity (2%). Forty-nine discrete lesions were assessable for local control. Median follow-up for assessable lesions was 16 months (range, 6 to 54 months). The median maximal tumor diameter was 2.7 cm (range, 0.4 to 5.8 cm). Local progression occurred in only three lesions at a median of 7.5 months (range, 7 to 13 months) after SBRT. Actuarial in-field local control rates at one and two years after SBRT were 95% and 92%, respectively. Among lesions with maximal diameter of 3 cm or less, 2-year local control was 100%. Median survival was 20.5 months. Conclusion: This multi-institutional, phase I/II trial demonstrates that high-dose liver SBRT is safe and effective for the treatment of patients with one to three hepatic metastases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Fong, Y., Fortner, J., Sun, R. L., Brennan, M. F., & Blumgart, L. H. (1999) · Annals of Surgery · doi:10.1097/00000658-199909000-00004 · Cited by 3,715
The linear-quadratic formula and progress in fractionated radiotherapy
Fowler, J. F. (1989) · The British Journal of Radiology · doi:10.1259/0007-1285-62-740-679 · Cited by 2,252
Timmerman, R., McGarry, R., Yiannoutsos, C., Papiez, L., Tudor, K., DeLuca, J., Ewing, M., Abdulrahman, R., DesRosiers, C., Williams, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.5937 · Cited by 1,556
Analysis of radiation-induced liver disease using the Lyman NTCP model
Dawson, L. A., Normolle, D., Balter, J. M., McGinn, C. J., Lawrence, T. S., & Ten Haken, R. K. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)02846-8 · Cited by 767
Park, C., Papiez, L., Zhang, S., Story, M., & Timmerman, R. D. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.10.059 · Cited by 651
Yamada, Y., Bilsky, M. H., Lovelock, D. M., Venkatraman, E. S., Toner, S., Johnson, J., Zatcky, J., Zelefsky, M. J., & Fuks, Z. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.11.046 · Cited by 542
Méndez Romero, A., Wunderink, W., Hussain, S. M., De Pooter, J. A., Heijmen, B. J. M., Nowak, P. C. J. M., Nuyttens, J. J., Brandwijk, R. P., Verhoef, C., Ijzermans, J. N. M., et al. (2006) · Acta Oncologica · doi:10.1080/02841860600897934 · Cited by 498
Stereotactic body radiation therapy of early-stage non–small-cell lung carcinoma: Phase I study
McGarry, R. C., Papiez, L., Williams, M., Whitford, T., & Timmerman, R. D. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.03.073 · Cited by 481
Cited by
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Iyengar, P., Wardak, Z., Gerber, D. E., Tumati, V., Ahn, C., Hughes, R. S., Dowell, J. E., Cheedella, N., Nedzi, L., Westover, K. D., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3501 · Cited by 1,047
Weickhardt, A. J., Scheier, B., Burke, J. M., Gan, G., Lu, X., Bunn, P. A., Aisner, D. L., Gaspar, L. E., Kavanagh, B. D., Doebele, R. C., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182745948 · Cited by 684
Self-citationWahl, D. R., Stenmark, M. H., Tao, Y., Pollom, E. L., Caoili, E. M., Lawrence, T. S., Schipper, M. J., & Feng, M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.4925 · Cited by 567
Stereotactic body radiotherapy for oligometastases
Tree, A. C., Khoo, V. S., Eeles, R. A., Ahmed, M., Dearnaley, D. P., Hawkins, M. A., Huddart, R. A., Nutting, C. M., Ostler, P. J., & van As, N. J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70510-7 · Cited by 524
Programmable probiotics for detection of cancer in urine
Danino, T., Prindle, A., Kwong, G. A., Skalak, M., Li, H., Allen, K., Hasty, J., & Bhatia, S. N. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa3519 · Cited by 467
Stereotactic Body Radiotherapy for Primary Hepatocellular Carcinoma
Andolino, D. L., Johnson, C. S., Maluccio, M., Kwo, P., Tector, A. J., Zook, J., Johnstone, P. A. S., & Cardenes, H. R. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.04.011 · Cited by 442
Self-citationMilano, M. T., Katz, A. W., Zhang, H., & Okunieff, P. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.08.036 · Cited by 439
Stereotactic body radiation therapy: a novel treatment modality
Lo, S. S., Fakiris, A. J., Chang, E. L., Mayr, N. A., Wang, J. Z., Papiez, L., Teh, B. S., McGarry, R. C., Cardenes, H. R., & Timmerman, R. D. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.188 · Cited by 419
Self-citationPD-1 Restrains Radiotherapy-Induced Abscopal Effect
Park, S. S., Dong, H., Liu, X., Harrington, S. M., Krco, C. J., Grams, M. P., Mansfield, A. S., Furutani, K. M., Olivier, K. R., & Kwon, E. D. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0138 · Cited by 389
Oligometastases and Oligo-recurrence: The New Era of Cancer Therapy
Niibe, Y., & Hayakawa, K. (2010) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyp167 · Cited by 359
Dose-Escalation Study of Single-Fraction Stereotactic Body Radiotherapy for Liver Malignancies
Goodman, K. A., Wiegner, E. A., Maturen, K. E., Zhang, Z., Mo, Q., Yang, G., Gibbs, I. C., Fisher, G. A., & Koong, A. C. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.08.020 · Cited by 323
Salama, J. K., Hasselle, M. D., Chmura, S. J., Malik, R., Mehta, N., Yenice, K. M., Villaflor, V. M., Stadler, W. M., Hoffman, P. C., Cohen, E. E. W., et al. (2012) · Cancer · doi:10.1002/cncr.26611 · Cited by 320
Stereotactic body radiotherapy for colorectal liver metastases: A pooled analysis
Chang, D. T., Swaminath, A., Kozak, M., Weintraub, J., Koong, A. C., Kim, J., Dinniwell, R., Brierley, J., Kavanagh, B. D., Dawson, L. A., et al. (2011) · Cancer · doi:10.1002/cncr.25997 · Cited by 302
Self-citationPalma, D. A., Haasbeek, C. J. A., Rodrigues, G. B., Dahele, M., Lock, M., Yaremko, B., Olson, R., Liu, M., Panarotto, J., Griffioen, G., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-305 · Cited by 302
Iyengar, P., Kavanagh, B. D., Wardak, Z., Smith, I., Ahn, C., Gerber, D. E., Dowell, J., Hughes, R., Abdulrahman, R., Camidge, D. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.7412 · Cited by 286
Self-citationDe Ruysscher, D., Wanders, R., van Baardwijk, A., Dingemans, A.-M. C., Reymen, B., Houben, R., Bootsma, G., Pitz, C., van Eijsden, L., Geraedts, W., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318262caf6 · Cited by 283
Ashworth, A., Rodrigues, G., Boldt, G., & Palma, D. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.07.026 · Cited by 282
The oligometastatic state—separating truth from wishful thinking
Palma, D. A., Salama, J. K., Lo, S. S., Senan, S., Treasure, T., Govindan, R., & Weichselbaum, R. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.96 · Cited by 277
Sinusoidal Obstruction Syndrome (Hepatic Veno-Occlusive Disease)
Fan, C. Q., & Crawford, J. M. (2014) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2014.10.002 · Cited by 274
Liu, Y., Crowe, W. N., Wang, L., Lu, Y., Petty, W. J., Habib, A. A., & Zhao, D. (2019) · Nature Communications · doi:10.1038/s41467-019-13094-5 · Cited by 254
Future cancer research priorities in the USA: a Lancet Oncology Commission
Jaffee, E. M., Dang, C. V., Agus, D. B., Alexander, B. M., Anderson, K. C., Ashworth, A., Barker, A. D., Bastani, R., Bhatia, S., Bluestone, J. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30698-8 · Cited by 208
Self-citationMahadevan, A., Blanck, O., Lanciano, R., Peddada, A., Sundararaman, S., D’Ambrosio, D., Sharma, S., Perry, D., Kolker, J., & Davis, J. (2018) · Radiation Oncology · doi:10.1186/s13014-018-0969-2 · Cited by 208
“In the subsequent report of the combined phase I/II multi-institutional results, 47 patients were treated to 63 liver metastases at 7 participating institutions [29].”
BackgroundLehrer, E. J., Singh, R., Wang, M., Chinchilli, V. M., Trifiletti, D. M., Ost, P., Siva, S., Meng, M.-B., Tchelebi, L., & Zaorsky, N. G. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.6146 · Cited by 196
Extracranial Oligometastases: A Subset of Metastases Curable With Stereotactic Radiotherapy
Corbin, K. S., Hellman, S., & Weichselbaum, R. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9651 · Cited by 185
“metastases has shown promising local control rates for treated metastases, ranging from 67% to 95%.(66,71,72,74,77,80-84) Two- to 3-year survival rates have been reported in the range of 30% to 64%(73,77,78,85) and Corbin, Hellman, and Weichselbaum”
BackgroundScorsetti, M., Comito, T., Tozzi, A., Navarria, P., Fogliata, A., Clerici, E., Mancosu, P., Reggiori, G., Rimassa, L., Torzilli, G., et al. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1833-x · Cited by 174
“While Rusthoven (Rusthoven et al. 2009), with a prescription dose of 60 Gy in 3 fractions, showed a decrease of LC for lesions >3 cm in diameter, our results have shown that LC is not correlated with the size of the lesions (less or larger than 3 cm in diameter), when a higher prescription dose is…”
BackgroundResultInfluentialGulley, J. L., Madan, R. A., Tsang, K.-Y., Arlen, P. M., Camphausen, K., Mohebtash, M., Kamrava, M., Schlom, J., & Citrin, D. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.615741 · Cited by 26
“Advances in our understanding of liver tolerance and treatment delivery and planning, including stereotactic body radiation therapy and respiratory gating, have made it possible to deliver tumoricidal doses to liver metastases with encouraging control rates [27,28].”
Background
Metadata
- Authors
- Rusthoven, K. E., Kavanagh, B. D., Cardenes, H., Stieber, V. W., Burri, S. H., Feigenberg, S. J., Chidel, M. A., Pugh, T. J., Franklin, W., Kane, M., Gaspar, L. E., & Schefter, T. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-04-01
- Volume
- 27
- Issue
- 10
- Pages
- 1572-1578
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4239112513
- Cited by
- 805
- References
- 17
- FWCI
- 44.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.